GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $750 million for an experimental cancer therapy from the privately owned Chinese biotech Chimagen Biosciences. The pharmaceuticals group will hand ...

FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences. Trispecific TCE targeting T cells ...

GSK to acquire potential best-in-class T cell-engager for multiple myeloma from Chimagen Biosciences: London, UK Wednesday, September 16, 2026, 09:00 Hrs [IST] GSK plc announced i ...

Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

All deal values reflect company disclosures. Where parties have not disclosed terms, they are reported as undisclosed. No ...

GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...

GSK will acquire a Chimagen trispecific T cell engager for multiple myeloma in a deal worth up to $750M. Here's what it means ...

The European stock markets closed lower in Tuesday trading as energy and defense sector stocks rallied, while bank and luxury goods stocks declined amid rising oil prices and bond yields. The Stoxx ...

GSK has agreed to pay up to $750 million for an experimental cancer therapy from the privately owned Chinese biotech Chimagen Biosciences. The pharmaceuticals group will hand over an undisclosed ...

the curiosity to learn, the willingness to adapt, the courage to be uncomfortable, and the commitment to solve real human problems will define the true technology change-makers ...